GET THE APP

A review of the newest multiparametric prostate MRI pro

Journal of Clinical & Experimental Oncology.ISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A review of the newest multiparametric prostate MRI protocol using reporting and data system version 2 (PI-RADSv2)


Sara Fardin, Michael Nguyentat, Shane Knipping, Alexander Ushinsky, Layla Shirkhoda, Alessandra Miranda Aguirre, Christopher Green, Edward Uchio, Chandana Lall and Roozbeh Houshyar

University of California, Irvine, USA
: J Clin Exp Oncol

Abstract


Prostate cancer is the second most common cancer among men, and thus, many stand to benefit from the advancement of prostate detection technology. Recently, multiparametric magnetic resonance imaging (mpMRI) has been developed as an adjuvant tool for prostate cancer screening. The European Society of Urogenital Radiology initially developed a set of guidelines, the Prostate Imaging– Reporting and Data System (PI-RADS) version 1, to standardize mpMRI image acquisition and prostate cancer reporting. Further refinement of the PI-RADS version 1 criteria resulted in the release of PI-RADS version 2 in 2015. Previous studies have validated PI-RADSv2 as useful tool for prostate cancer screening, and thus, can potentially aid in early detection of prostate cancer while decreasing the need for unnecessary prostate biopsy procedures, costs, and complications. Thus, a radiologist fluent in the PIRADSv2 criteria can help detect early prostate cancer and contribute to the overall improvement of patient care. This educational poster will review the multiparametric prostate MRI (mpMRI) protocols per recommendations from Prostate Imaging– Reporting and Data System Version 2 (PI-RADSv2) with an emphasis on 3T imaging without use of endorectal coil, and technical specifications for proper mpMRI studies. It will also review the PI-RADSv2 grading system, with distinction between transitional and peripheral zone lesions, and help reinforce the guidelines through sample cases.

Biography


Sara Fardin has completed her Medical School in Tehran University of Medical Sciences and Radiology-Molecular Imaging Research Fellowship in the University of Pennsylvania. She is currently working as a Research Fellow in University of California, Irvine.

Email: sfardin@uci.edu

Track Your Manuscript

Media Partners